Reliability
Reproducible results, standardised protocols and clear clinical reporting.
Precision Oncology & Genomics
OncoDNA — complete NGS solutions for oncology
OncoDNA is a Belgian biotechnology company focused on NGS products for precision oncology. It was founded in 2012 in Gosselies, Belgium, with the aim of creating complete NGS solutions that help physicians select the most suitable treatment based on the molecular profile of the tumour. OncoDEEP®, OncoSELECT® and the OncoKDM® clinical software are used in many laboratories worldwide.
- 2012 Founded in Belgium
- 100k+ Tests in the database
- ISO 13485 Certification
- 35+ Countries
About the company
Partner in precision oncology
OncoDNA's core mission is to improve patient outcomes by enabling physicians, biotech and pharmaceutical companies and researchers to fully harness the potential of precision medicine. To this end, the company is building an ecosystem of partners involved in the entire process: from translational research and drug development to patient treatment, follow-up and the reimbursement of testing and care.
Building on many years of experience and intensive development, OncoDNA has created cutting-edge solutions for oncology. Its unique portfolio rests on three main pillars: tumour biomarker tests, genomic services in oncology and tools for interpreting biological data. Its proprietary tests (OncoDEEP®, OncoSELECT®, OncoXPLORE®) and clinical decision-support software (OncoKDM®, OncoCDI®) are now used by laboratories and biopharma partners in more than 35 countries.
Mission & values
Bringing innovation to molecular profiling
OncoDNA aims to deliver high-quality tools for precision oncology.
Quality
Accredited laboratory processes, certifications and independent QC of every batch.
Innovation
New biomarker tests, clinical software and methodological advances in precision oncology.
Speed
Fast results for timely decisions on optimal treatment.
Products
Portfolio from OncoDNA
Complete solutions for precision oncology, from comprehensive profiling of solid tumours to treatment monitoring by liquid biopsy.
OncoDEEP®
Comprehensive genomic profiling of solid tumours: 638 DNA + 22 RNA driver genes, TMB / MSI / HRD / LOH, fusions. From sample preparation to report in 5 days. Compatible with Illumina, MGI and Element Aviti.
Product detailsOncoSELECT®
Targeted liquid biopsy test: 74 genes, LOD 0.25%. Treatment monitoring, resistance detection and non-invasive patient follow-up without repeat biopsies.
Product detailsOncoXPLORE®
A unique multi-omics liquid biopsy test. It combines genomics and fragmentomics for early detection and monitoring across tumour types.
Product detailsLet's start
Interested in the OncoDNA portfolio?
We will be happy to introduce the individual solutions in more detail, help with sample preparation and provide full training.